TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
TC BioPharm has been awarded a $250,000 non-dilutive grant from ScaleReady's G-Rex® Grant Program to support TCB008 manufacturing process optimizations over the next 18 months. The company aims to increase yields while reducing manufacturing costs by over 80%. The grant will help expedite process optimizations, allowing for expanded yields with a shortened manufacturing process in the first half of 2025, which is 12 months ahead of schedule. The optimizations will increase TCB008 production rate at the existing Maxim Park facility without increasing overhead costs.
TC BioPharm ha ricevuto un finanziamento non diluitivo di 250.000 dollari dal Programma di Sovvenzioni G-Rex® di ScaleReady, per supportare le ottimizzazioni del processo di produzione di TCB008 nei prossimi 18 mesi. L'azienda punta ad aumentare i rendimenti riducendo i costi di produzione di oltre l'80%. La sovvenzione aiuterà a velocizzare le ottimizzazioni dei processi, consentendo un incremento dei rendimenti con un processo di produzione ridotto nella prima metà del 2025, ovvero 12 mesi prima del previsto. Le ottimizzazioni aumenteranno il tasso di produzione di TCB008 presso l'impianto esistente di Maxim Park senza aumentare i costi generali.
TC BioPharm ha sido premiada con una subvención no dilutiva de $250,000 del Programa de Subvenciones G-Rex® de ScaleReady para apoyar las optimizaciones del proceso de fabricación de TCB008 durante los próximos 18 meses. La empresa pretende aumentar los rendimientos mientras reduce los costos de fabricación en más del 80%. La subvención ayudará a acelerar las optimizaciones del proceso, permitiendo mayores rendimientos con un proceso de fabricación acortado en la primera mitad de 2025, que está 12 meses por delante de lo programado. Las optimizaciones aumentarán la tasa de producción de TCB008 en la instalación existente de Maxim Park sin incrementar los costos generales.
TC BioPharm는 ScaleReady의 G-Rex® 보조금 프로그램으로부터 250,000달러의 비희석 보조금을 수여받아 향후 18개월 동안 TCB008 제조 공정 최적화를 지원하게 됩니다. 이 회사는 제조 비용을 80% 이상 줄이면서 수익성을 높이는 것을 목표로 하고 있습니다. 이 보조금은 공정 최적화를 신속하게 진행하는 데 도움이 되어, 2025년 상반기에는 12개월 앞당겨 짧은 제조 공정으로 확대된 수익성과 함께 목표를 달성할 수 있도록 합니다. 최적화는 Maxim Park의 기존 시설에서 TCB008의 생산률을 높이는데 기여하며, 운영 비용의 증가 없이 가능합니다.
TC BioPharm a reçu une subvention non dilutive de 250 000 $ du programme de subventions G-Rex® de ScaleReady pour soutenir les optimisations du processus de fabrication de TCB008 au cours des 18 prochains mois. L'entreprise vise à augmenter les rendements tout en réduisant les coûts de fabrication de plus de 80 %. La subvention contribuera à accélérer les optimisations des processus, permettant ainsi d'élargir les rendements avec un processus de fabrication raccourci au premier semestre 2025, soit 12 mois d'avance sur le calendrier. Les optimisations augmenteront le taux de production de TCB008 dans l'installation existante de Maxim Park sans augmenter les coûts généraux.
TC BioPharm hat einen nicht verwässernden Zuschuss in Höhe von 250.000 Dollar vom G-Rex®-Zuschussprogramm von ScaleReady erhalten, um Optimierungen des Herstellungsprozesses von TCB008 in den nächsten 18 Monaten zu unterstützen. Das Unternehmen strebt an, die Ausbeuten zu steigern und gleichzeitig die Herstellungskosten um über 80% zu senken. Der Zuschuss wird dazu beitragen, die Prozessoptimierungen zu beschleunigen, was in der ersten Hälfte von 2025 zu einer erhöhten Ausbeute bei kürzerem Herstellungsprozess führt, d.h. 12 Monate früher als geplant. Die Optimierungen werden die Produktionsrate von TCB008 in der bestehenden Maxim Park-Anlage erhöhen, ohne die Gemeinkosten zu steigern.
- Secured $250,000 in non-dilutive funding
- Expected 80% reduction in manufacturing costs
- Production process optimization timeline accelerated by 12 months
- Increased production capacity without additional overhead costs
- None.
Insights
This
The implementation strategy appears solid, focusing on maximizing existing facility capacity without increasing overhead costs. This approach to manufacturing efficiency could significantly improve TCBP's market position, especially considering the current challenges in cell therapy manufacturing costs. The partnership with ScaleReady and access to their consortium's expertise adds valuable technical support beyond the monetary grant.
The non-dilutive funding, while modest at
The accelerated timeline for implementation could positively impact the company's cash runway and time to market. The focus on making TCB008 more economical could enhance market adoption and commercial viability, particularly important in the cost-sensitive healthcare market.
The G-Rex® Grant Program, launched by ScaleReady alongside Wilson Wolf Manufacturing and the Bio-Techne Corporation, is a
The
"It's fantastic to see grants offered in support of cell therapy products using the G-Rex® platform, and we're excited to reveal the benefits of our program work over the next 18 months," said Dr. Lauren Bor. "We announced earlier in 2024 that we were developing the TCB008 manufacturing process to increase yields while reducing costs with the target of increasing our yield by a large scale and decreasing our costs by over
Joseph Mullen, Head of Production, who will work with Dr. Lauren Bor's team to implement the developed process optimizations in the latter half of 2025, said, "We look forward to implementing the G-Rex® platform optimizations, developed using the awarded grant. These developments will increase the rate of TCB008 manufacture within the existing Maxim Park facility without the need to increase overhead costs."
"We appreciate ScaleReady's G-Rex® Grant Program and ScaleReady's commitment to innovation in the cell therapy manufacturing space," said Bryan Kobel, CEO of TC BioPharm. "This non-dilutive grant will continue to support product development and manufacture as we advance our Phase 2B clinical trial for the treatment of patients with acute myeloid leukemia. The work being done to further advance scaling production of TCB008 to commercial levels will be accelerated by this funding and bring increased cost savings, making TCB008 affordable for all patients and potentially one of the most economical cell therapy options."
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Press Release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the Company's intent or ability to affect any budget savings or execute any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees but involve known and unknown risks, uncertainties, and other important factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Press Release, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Press Release. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
About ScaleReady
ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing. ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treating acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-awarded-non-dilutive-funding-scalereadys-g-rex-grant-302302730.html
SOURCE TC BioPharm
FAQ
What is the value of the G-Rex Grant awarded to TC BioPharm (TCBP)?
When will TC BioPharm (TCBP) implement the new TCB008 manufacturing process?
How much cost reduction does TC BioPharm (TCBP) expect from the TCB008 manufacturing optimization?
